Ashley N. Crowl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ashley N. Crowl has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Sarah Shrader
University of Kansas, School of Pharmacy, Lawrence, Kansas
3 shared publications- Amy Robertson
Pharmacy Practice, University of Kansas School of Pharmacy- Wichita Regional Campus, 1010 N. Kansas St, Wichita, KS 67214, United States
1 shared publication Angela Baalmann
University of Kansas, School of Pharmacy, Lawrence, Kansas
1 shared publicationAnne Schullo-Feulner
University of Minnesota College of PharmacyMinneapolis, MN, USA Methodist Hospital, St Louis Park, MN, USA
1 shared publication- Caitlin M. Gibson
Virginia Commonwealth University School of Pharmacy
1 shared publication Candice Coffey
University of Kansas, School of Medicine, Kansas City, Kansas
1 shared publication
Latest Publications
- Open Access
- 15 July 2025
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 89 (8) , 101460
Exploration of Psychosocial Hazards: Core Values, Justice and Fairness, and Social Support to Address Workforce Well-Being
- 15 July 2025
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 89 (8) , 101460
Open AccessExploration of Psychosocial Hazards: Core Values, Justice and Fairness, and Social Support to Address Workforce Well-Being
- 17 November 2022
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 14 (12) , 1512-1517
Evaluation of a simulation-based learning activity for communicating about at-risk opioid behaviors in a community pharmacy setting
- 17 November 2022
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 14 (12) , 1512-1517
Evaluation of a simulation-based learning activity for communicating about at-risk opioid behaviors in a community pharmacy setting
- 23 February 2022
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 87 (1)
Interprofessional Medication Error Disclosure Training Using a Telehealth Consultation Simulation
Objective. Health profession students must develop collaborative skills to disclose errors effectively and improve patient safety. We proposed that an interprofessional (IP) simulation utilizing telehealth technology would provide medical and pharmacy students the opportunity to practice, develop, and grow in their confidence and skills of working collaboratively and disclosing medication errors. Methods. A three-phase IP student simulation was developed. Phase 1 included individual student preparation. An IP telehealth consultation encounter occurred in phase 2 for the error disclosure between the pharmacy and medical students. Phase 3 included faculty-led IP debrief sessions. A pre- and post-simulation survey assessed students’ experiences regarding their confidence in error disclosure, use of telehealth technology, and the role of the community pharmacist. Faculty evaluated pharmacy student performance utilizing a 12-point rubric. Results. Pre-simulation survey responses (n=173) were compared to post-simulation survey responses (n=140). Significant changes were seen for all students’ confidence in error disclosure and use of telehealth technology. No significant change was noted in the students’ understanding of the community pharmacists’ role on the IP team. Pharmacy student performance-based rubric data (n=148) revealed a median score of 7/12 for error disclosure and IP communication items. Conclusion. Medical and pharmacy students perceived confidence improved in IP error disclosure and use of telehealth consultation technology through this IP simulation. Pharmacy students’ error disclosure and IP communication skill development were assessed through this simulation.
- 23 February 2022
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 87 (1)
Interprofessional Medication Error Disclosure Training Using a Telehealth Consultation Simulation
Objective. Health profession students must develop collaborative skills to disclose errors effectively and improve patient safety. We proposed that an interprofessional (IP) simulation utilizing telehealth technology would provide medical and pharmacy students the opportunity to practice, develop, and grow in their confidence and skills of working collaboratively and disclosing medication errors. Methods. A three-phase IP student simulation was developed. Phase 1 included individual student preparation. An IP telehealth consultation encounter occurred in phase 2 for the error disclosure between the pharmacy and medical students. Phase 3 included faculty-led IP debrief sessions. A pre- and post-simulation survey assessed students’ experiences regarding their confidence in error disclosure, use of telehealth technology, and the role of the community pharmacist. Faculty evaluated pharmacy student performance utilizing a 12-point rubric. Results. Pre-simulation survey responses (n=173) were compared to post-simulation survey responses (n=140). Significant changes were seen for all students’ confidence in error disclosure and use of telehealth technology. No significant change was noted in the students’ understanding of the community pharmacists’ role on the IP team. Pharmacy student performance-based rubric data (n=148) revealed a median score of 7/12 for error disclosure and IP communication items. Conclusion. Medical and pharmacy students perceived confidence improved in IP error disclosure and use of telehealth consultation technology through this IP simulation. Pharmacy students’ error disclosure and IP communication skill development were assessed through this simulation.
- 1 July 2021
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 13 (7) , 779-783
Determining the impact of an interprofessional simulation focused on social determinants of health among pharmacy students
- 1 July 2021
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 13 (7) , 779-783
Determining the impact of an interprofessional simulation focused on social determinants of health among pharmacy students
- 1 April 2020
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 84 (4) , 421-426
Assessing Self-Perceived Interprofessional Collaborative Competency on Advanced Pharmacy Practice Experiences Through Interprofessional Simulations
Objective. To implement and assess the impact of Doctor of Pharmacy (PharmD) students participating in a required interprofessional (IP) simulation during an advanced pharmacy practice experience (APPE). Methods. Fourth-year PharmD students completing APPEs were required to participate in one of three IP simulations during the 2016-2017 academic year to improve their interprofessional teamwork and collaboration skills. Pharmacy student self-perception of IP competence was measured by the Interprofessional Collaborative Competency Attainment Survey (ICCAS), administered in a retrospective pre-/post-test design. Responses were analyzed using descriptive statistics to obtain an overview of the data. Paired t tests were used to compare the pre- and post-test results. Results. During the 2016-2017 academic year, 157 PharmD students were assigned to complete an IP simulation. Student scores on the six subscales of the ICCAS (communication, collaboration, roles and responsibility, collaborative patient-centered approach, conflict management, and team functioning) were compared. Scores in all categories significantly increased after completion of the simulation. Conclusion. Following participation in an IP simulation, PharmD students felt competent to engage in IP collaboration, and this, along with their performance on APPEs, determined their practice-readiness for IP teamwork upon graduation.
- 1 April 2020
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 84 (4) , 421-426
Assessing Self-Perceived Interprofessional Collaborative Competency on Advanced Pharmacy Practice Experiences Through Interprofessional Simulations
Objective. To implement and assess the impact of Doctor of Pharmacy (PharmD) students participating in a required interprofessional (IP) simulation during an advanced pharmacy practice experience (APPE). Methods. Fourth-year PharmD students completing APPEs were required to participate in one of three IP simulations during the 2016-2017 academic year to improve their interprofessional teamwork and collaboration skills. Pharmacy student self-perception of IP competence was measured by the Interprofessional Collaborative Competency Attainment Survey (ICCAS), administered in a retrospective pre-/post-test design. Responses were analyzed using descriptive statistics to obtain an overview of the data. Paired t tests were used to compare the pre- and post-test results. Results. During the 2016-2017 academic year, 157 PharmD students were assigned to complete an IP simulation. Student scores on the six subscales of the ICCAS (communication, collaboration, roles and responsibility, collaborative patient-centered approach, conflict management, and team functioning) were compared. Scores in all categories significantly increased after completion of the simulation. Conclusion. Following participation in an IP simulation, PharmD students felt competent to engage in IP collaboration, and this, along with their performance on APPEs, determined their practice-readiness for IP teamwork upon graduation.
- 1 February 2020
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 12 (2) , 156-162
Potential best practices for assessment of interprofessional team-ready behaviors on APPEs
- 1 February 2020
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 12 (2) , 156-162
Potential best practices for assessment of interprofessional team-ready behaviors on APPEs
- 7 August 2014
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 48 (11) , 1479-1483
Warfarin Monitoring in Antiphospholipid Syndrome and Lupus Anticoagulant
Objective: To review the available literature on international normalized ratio (INR) and chromogenic factor X (CFX) monitoring in patients with antiphospholipid syndrome (APS), specifically lupus anticoagulant (LA), and furthermore, to identify benefits of one monitoring test compared with the other in the presence of LA. Data Sources: A literature search was conducted through MEDLINE (1946-May 2014) utilizing the following MeSH terms chromogenic compounds, anticoagulants, and factor X. Further articles were identified from original literature citations. Study Selection: All English-language studies were included that involved INR and/or CFX monitoring in APS patients that focused on a therapeutic anticoagulation level with warfarin therapy. Data Synthesis: A total of 55 articles were identified, of which nine are referenced because of their relevance for this review: three articles focus on the efficacy of utilizing INR monitoring in patients with APS, five focus on CFX compared with INR for therapeutic warfarin dosing, and one compares different thromboplastins utilizing both INR and CFX monitoring. INR monitoring in patients with APS, specifically LA, was not found to be reliable because thromboplastin reagents are sensitive to LA. Furthermore, when INR was compared to CFX, patients with LA had supratherapeutic INRs despite having CFX within goal range. Conclusions: In a subgroup of APS patients, INR monitoring may not be safe for determining the dose of warfarin because their INR values can be falsely elevated. Although CFX monitoring is more accurate, it too comes with its own downsides. Managing warfarin therapy in the APS population needs to be individualized.
- 7 August 2014
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 48 (11) , 1479-1483
Warfarin Monitoring in Antiphospholipid Syndrome and Lupus Anticoagulant
Objective: To review the available literature on international normalized ratio (INR) and chromogenic factor X (CFX) monitoring in patients with antiphospholipid syndrome (APS), specifically lupus anticoagulant (LA), and furthermore, to identify benefits of one monitoring test compared with the other in the presence of LA. Data Sources: A literature search was conducted through MEDLINE (1946-May 2014) utilizing the following MeSH terms chromogenic compounds, anticoagulants, and factor X. Further articles were identified from original literature citations. Study Selection: All English-language studies were included that involved INR and/or CFX monitoring in APS patients that focused on a therapeutic anticoagulation level with warfarin therapy. Data Synthesis: A total of 55 articles were identified, of which nine are referenced because of their relevance for this review: three articles focus on the efficacy of utilizing INR monitoring in patients with APS, five focus on CFX compared with INR for therapeutic warfarin dosing, and one compares different thromboplastins utilizing both INR and CFX monitoring. INR monitoring in patients with APS, specifically LA, was not found to be reliable because thromboplastin reagents are sensitive to LA. Furthermore, when INR was compared to CFX, patients with LA had supratherapeutic INRs despite having CFX within goal range. Conclusions: In a subgroup of APS patients, INR monitoring may not be safe for determining the dose of warfarin because their INR values can be falsely elevated. Although CFX monitoring is more accurate, it too comes with its own downsides. Managing warfarin therapy in the APS population needs to be individualized.